301 related articles for article (PubMed ID: 24262410)
1. [Up-to-date on the treatment of benign prostatic hyperplasia. Which adenoma to treat and how to do it?].
Lahlaidi K; Ariane MM; Fontaine E
Rev Med Interne; 2014 Mar; 35(3):189-95. PubMed ID: 24262410
[TBL] [Abstract][Full Text] [Related]
2. [Urination disorders in the man: differential diagnoses and therapy of benign prostate syndrome].
Meyer D; Schmid HP
Praxis (Bern 1994); 2013 Oct; 102(20):1237-42. PubMed ID: 24088234
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
[TBL] [Abstract][Full Text] [Related]
4. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study.
Lukacs B; Cornu JN; Aout M; Tessier N; Hodée C; Haab F; Cussenot O; Merlière Y; Moysan V; Vicaut E
Eur Urol; 2013 Sep; 64(3):493-501. PubMed ID: 23465519
[TBL] [Abstract][Full Text] [Related]
5. Management of Benign Prostatic Hyperplasia in Older Adults.
Woodard TJ; Manigault KR; McBurrows NN; Wray TL; Woodard LM
Consult Pharm; 2016; 31(8):412-24. PubMed ID: 27535076
[TBL] [Abstract][Full Text] [Related]
6. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
7. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
[TBL] [Abstract][Full Text] [Related]
8. Benign Prostatic Hyperplasia.
Langan RC
Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
[TBL] [Abstract][Full Text] [Related]
9. Benign prostatic hyperplasia: current clinical practice.
Djavan B; Eckersberger E; Finkelstein J; Espinosa G; Sadri H; Brandner R; Shah O; Lepor H
Prim Care; 2010 Sep; 37(3):583-97, ix. PubMed ID: 20705200
[TBL] [Abstract][Full Text] [Related]
10. Treatment of benign prostatic hyperplasia.
Pinheiro LC; Martins Pisco J
Tech Vasc Interv Radiol; 2012 Dec; 15(4):256-60. PubMed ID: 23244720
[TBL] [Abstract][Full Text] [Related]
11. Managing the multiple symptoms of benign prostatic hyperplasia.
Miner M
J Fam Pract; 2012 Jun; 61(6 Suppl):S5-10. PubMed ID: 22670247
[No Abstract] [Full Text] [Related]
12. Diagnosis and management of benign prostatic hyperplasia.
Edwards JL
Am Fam Physician; 2008 May; 77(10):1403-10. PubMed ID: 18533373
[TBL] [Abstract][Full Text] [Related]
13. [Management of benign prostate syndrome].
Herlemann A; Strittmatter F; Stief CG; Gratzke C
MMW Fortschr Med; 2013 Aug; 155(14):39-42. PubMed ID: 24006594
[No Abstract] [Full Text] [Related]
14. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.
Sausville J; Naslund M
Int J Clin Pract; 2010 Dec; 64(13):1740-5. PubMed ID: 21070524
[TBL] [Abstract][Full Text] [Related]
15. [Conservative treatment of benign prostatic hyperplasia].
Romics I
Orv Hetil; 2008 Oct; 149(40):1875-80. PubMed ID: 18815106
[TBL] [Abstract][Full Text] [Related]
16. Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.
Singapore Urological Association Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Guidelines Committee 2015
Singapore Med J; 2017 Aug; 58(8):473-480. PubMed ID: 28848988
[TBL] [Abstract][Full Text] [Related]
17. Benign Prostatic Hyperplasia Implications for Pharmacologic Treatment and Perioperative Care.
Leedahl DD; Vo PH; Maxson PM; Lovely JK
J Pharm Pract; 2013 Feb; 26(1):52-8. PubMed ID: 22797835
[TBL] [Abstract][Full Text] [Related]
18. [Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología].
Castiñeiras Fernández J; Cozar Olmo JM; Fernández-Pro A; Martín JA; Brenes Bermúdez FJ; Naval Pulido E; Molero JM; Pérez Morales D; ; ; ;
Actas Urol Esp; 2010 Jan; 34(1):24-34. PubMed ID: 20223130
[TBL] [Abstract][Full Text] [Related]
19. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
20. Urological disorders in men: urinary incontinence and benign prostatic hyperplasia.
Miller SW; Miller MS
J Pharm Pract; 2011 Aug; 24(4):374-85. PubMed ID: 21984774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
